ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of “Moderate Buy” by Brokerages

Posted by Stanley Muller on May 29th, 2026

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $28.60.

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald increased their price objective on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday. Leerink Partners set a $26.00 target price on ARS Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Northland Securities started coverage on ARS Pharmaceuticals in a research note on Thursday, April 9th. They set an “outperform” rating and a $25.00 price target on the stock. Wall Street Zen upgraded ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Zacks Research raised ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th.

Check Out Our Latest Stock Report on SPRY

Institutional Trading of ARS Pharmaceuticals

Several hedge funds have recently bought and sold shares of SPRY. Rubric Capital Management LP raised its holdings in ARS Pharmaceuticals by 29.0% during the first quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock worth $64,240,000 after buying an additional 1,800,000 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of ARS Pharmaceuticals by 14.8% during the fourth quarter. Aberdeen Group plc now owns 3,556,049 shares of the company’s stock valued at $41,428,000 after buying an additional 459,027 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of ARS Pharmaceuticals by 7.3% during the third quarter. Vanguard Group Inc. now owns 3,500,303 shares of the company’s stock valued at $35,178,000 after buying an additional 237,630 shares during the last quarter. State Street Corp increased its position in shares of ARS Pharmaceuticals by 11.3% during the fourth quarter. State Street Corp now owns 3,223,581 shares of the company’s stock worth $37,555,000 after acquiring an additional 328,325 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of ARS Pharmaceuticals during the fourth quarter worth about $36,912,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Performance

NASDAQ:SPRY opened at $9.40 on Friday. The company has a quick ratio of 4.77, a current ratio of 4.94 and a debt-to-equity ratio of 2.79. ARS Pharmaceuticals has a twelve month low of $6.66 and a twelve month high of $18.90. The company has a fifty day moving average of $8.17 and a 200-day moving average of $9.24. The firm has a market capitalization of $933.42 million, a P/E ratio of -4.68 and a beta of 0.93.

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%.The company had revenue of $22.68 million for the quarter, compared to the consensus estimate of $22.20 million. As a group, sell-side analysts anticipate that ARS Pharmaceuticals will post -1.75 EPS for the current year.

About ARS Pharmaceuticals

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.